Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy.
Ontology highlight
ABSTRACT: The promising development of adoptive immunotherapy over the last four decades has revealed numerous therapeutic approaches in which dedicated immune cells are modified and administered to eliminate malignant cells. Starting in the early 1980s, lymphokine activated killer (LAK) cells were the first ex vivo generated NK cell-enriched products utilized for adoptive immunotherapy. Over the past decades, various immunotherapies have been developed, including cytokine-induced killer (CIK) cells, as a peripheral blood mononuclear cells (PBMCs)-based therapeutic product, the adoptive transfer of specific T and NK cell products, and the NK cell line NK-92. In addition to allogeneic NK cells, NK-92 cell products represent a possible "off-the-shelf" therapeutic concept. Recent approaches have succes
SUBMITTER: Wendel P
PROVIDER: S-EPMC8004685 | biostudies-literature | 2021 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA